Tonix Pharmaceuticals Holding Corp. (TNXP) Releases Earnings Results
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced its earnings results on Monday. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.13, Bloomberg Earnings reports.
Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) traded down 1.28% during midday trading on Tuesday, hitting $3.09. 22,016 shares of the company were exchanged. Tonix Pharmaceuticals Holding Corp. has a one year low of $3.07 and a one year high of $28.00. The stock’s market capitalization is $23.13 million. The firm’s 50-day moving average price is $4.02 and its 200-day moving average price is $3.26.
In related news, Director Ernest Mario sold 6,105 shares of the firm’s stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $4.28, for a total value of $26,129.40. Following the completion of the transaction, the director now owns 63,073 shares in the company, valued at approximately $269,952.44. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Seth Lederman acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 20th. The stock was acquired at an average price of $4.22 per share, with a total value of $84,400.00. Following the acquisition, the chief executive officer now owns 7,912 shares in the company, valued at $33,388.64. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 30,000 shares of company stock worth $128,050. 4.00% of the stock is currently owned by corporate insiders.
An institutional investor recently raised its position in Tonix Pharmaceuticals Holding Corp. stock. Vanguard Group Inc. raised its position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 184,377 shares of the company’s stock after buying an additional 41,264 shares during the period. Vanguard Group Inc. owned 2.46% of Tonix Pharmaceuticals Holding Corp. worth $799,000 as of its most recent filing with the SEC. 17.50% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Tonix Pharmaceuticals Holding Corp. (TNXP) Releases Earnings Results” was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/15/tonix-pharmaceuticals-holding-corp-tnxp-releases-earnings-results.html.
Separately, Aegis started coverage on shares of Tonix Pharmaceuticals Holding Corp. in a research note on Monday, June 26th. They issued a “buy” rating and a $10.00 target price for the company.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.